505b2 ndas in the era of covid-19 and beyond
Published 4 years ago • 73 plays • Length 58:37Download video MP4
Download video MP3
Similar videos
-
55:29
the 505(b)(2) nda pathway - an innovative fda strategy that everyone should understand webinar
-
1:53:41
role of biological clocks and other biomarkers of aging in regulatory development
-
1:56:23
wow or yeow?! fda outlook for 2021 and beyond
-
8:31
fda 505(b)(2) applications seminar part iv: the thin line between a 505(j) and 505(b)(2)
-
14:31
fda 505(b)(2) applications seminar part viii: q&a and discussion of 505(b)(2) applications
-
1:04
why generic drug makers may benefit from 505b2 approval – drugpatentwatch
-
2:00
durvalumab plus danvatirsen for r/m hnscc: exciting scores data
-
0:47
dr. nikita almond's research
-
5:32
fda 505(b)(2) applications seminar part vi: recent statistics on 505(b)(2) ndas
-
12:36
concurrent resurgence of rsv and other respiratory viruses 2022 - roberta l. debiasi, md, ms
-
13:04
fda 505(b)(2) applications seminar part vii: case studies on 505(b)(2) applications
-
1:56:42
wow! or yeow? holy cow! and what now?
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
1:00
dr. eleftherios mamounas on predicting the risk of dcis recurrence
-
6:13
fda 505(b)(2) applications seminar part iii: developing a 505(b)(2) application
-
0:54
nsabp b-51: can we forego radiation in early breast cancer? | #cancer #oncology
-
1:37
results for durvalumab in the second-line treatment of nsclc
-
6:50
qd251 - eosinophilia in ra